The Department of War is required to establish an integrated pharmacy benefits program for the Military Health System, involving the selection of pharmaceutical agents for the Uniform Formulary based on clinical and cost effectiveness. A Request for Quotation has been issued for drug classes to be reviewed at the August 2026 Pharmacy and Therapeutics Committee meeting, specifically ADHD Agents and BRAF-MEK Inhibitors. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements and Additional Discount Program Agreements based on the formulary decision. A pre-quotation teleconference is scheduled for May 13, 2026. No budget amounts or performance location are specified.